ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

lazertinib

Also written as “Lazertinib”, “Lazertinib 240 mg/160 mg” and “YH25448”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Osteoarthritis, Knee, led by 4 companies.

Drug pageLazertinib: every studyAll 31 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 23, 202018 company-led studies, 6 open or runningLicense: Yuhan → Janssen (Johnson & Johnson), Nov 2018Next primary completion: Feb 12, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson125 open or runningphase 3since Jul 23, 2020Aug 21, 2019Feb 12, 2027phase 1 · NCT04077463
Yuhanits history only40 open or runningphase 3since Jan 14, 2020Jan 26, 2017none ahead
Abionits history only11 open or runningphase 2since Sep 4, 2022Sep 4, 2022Feb 2029phase 2 · NCT05541822
BUZZZ Pharmaceuticalsits history only10 open or runningphase 2since Jul 22, 2021Jul 22, 2021none ahead

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

How Abion and BUZZZ Pharmaceuticals relate to it is not in the registry or these sources.

History and studies of Johnson & Johnson only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2017Named lazertinibINNProposed as its International Nonproprietary Name in WHO's List 117 · before, YH25448
  2. Nov 5, 2018Janssen (Johnson & Johnson) licensed it from YuhanLicenseEverywhere outside South Korea · announced · Yuhan (release)
  3. Aug 21, 2019First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT04075396 · 29 enrolled · United States, Spain, United Kingdom
  4. Aug 30, 2019Phase 1 study in Carcinoma, Non-Small-Cell LungNCT04077463 · 701 enrolled · United States, China, France and more
  5. May 28, 20202 phase 1 studies in HealthyNCT04410094, NCT04410081
  6. Jul 23, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04487080 · 1,074 enrolled · United States, Argentina, Australia and more
  7. Jul 30, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04988295 · 776 enrolled · United States, Argentina, Belgium and more
  8. Sep 17, 2021Phase 1 study in HealthyNCT05076877 · 20 enrolled · United States
  9. Nov 2, 2021Phase 1 study in Hepatic ImpairmentNCT05112952 · 16 enrolled · Germany
  10. Feb 15, 2023Phase 1 study in HealthyNCT05742594 · 64 enrolled · United States
  11. Jun 1, 2023Phase 1 study in HealthyNCT05896683 · 72 enrolled · Belgium
  12. Oct 30, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06667076 · 480 planned · United States, Belgium, Finland and more
  13. May 8, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07586202 · 68 planned · United States, Canada, China and more

Ahead

  1. Feb 12, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT04077463
  2. Mar 2, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07586202
  3. May 23, 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06667076

TargetBeta

EGFR →read by rule
“An orally available third-generation, selective inhibitor of certain forms of the epidermal growth factor receptor (EGFR) with activating mutations, including the resistance mutation T790M, exon 19 deletions (Del19), and the L858R mutation, ”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

All 12 Johnson & Johnson leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07586202Carcinoma, Non-Small-Cell Lung · United States, Canada, China and more2RecruitingMar 2, 202868
NCT06667076Carcinoma, Non-Small-Cell Lung · United States, Belgium, Finland and more2RecruitingMay 23, 2029480
NCT05896683Healthy · Belgium1CompletedSep 1, 202372
NCT05742594Healthy · United States1CompletedMar 31, 202364
NCT05112952Hepatic Impairment · Germany1CompletedJul 11, 202216
NCT05076877Healthy · United States1CompletedFeb 10, 202220
NCT04988295Carcinoma, Non-Small-Cell Lung · United States, Argentina, Belgium and more3Active, not recruitingJul 10, 2023776
NCT04487080Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingAug 11, 20231,074
NCT04410094Healthy · United States1CompletedDec 30, 202032
NCT04410081Healthy · Netherlands1CompletedMar 2, 20218
NCT04077463Carcinoma, Non-Small-Cell Lung · United States, China, France and more1Active, not recruitingFeb 12, 2027701
NCT04075396Carcinoma, Non-Small-Cell Lung · United States, Spain, United Kingdom2CompletedJan 8, 202129

How it is read

Names in the registry

  • “Lazertinib”, 12 entries
  • “Lazertinib 240 mg/160 mg”, 1 entry
  • “YH25448”, 1 entry
  • “Lazertinib(G001)”, 1 entry
  • “Lazertinib(G002)”, 1 entry

Codes read as this program: G001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.